Peer-reviewed veterinary case report
Using mycophenolate to treat immune eye disease in dogs
By Li Puma, Margaret C. & Diehl, Kathryn A.·Published in Veterinary Record Case Reports·2021·Department of Small Animal Medicine and Surgery University of Georgia College of Veterinary Medicine Athens Georgia USA, United States·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The use of systemic mycophenolate in canine immune‐mediated ophthalmic disease
- Species:
- dog
Plain-English summary
A group of dogs with eye problems caused by their immune system attacking their eyes were treated with a medication called mycophenolate to help reduce inflammation. Out of 23 dogs, 18 showed improvement, either completely or partially, and only a few needed additional medications. Some dogs experienced stomach issues, but one dog's symptoms improved when the mycophenolate dose was cut in half while still keeping the eye inflammation under control. Overall, mycophenolate appears to be a helpful option for managing these eye conditions in dogs.
People also search for: dog eye problems treatment · immune-mediated eye disease in dogs · mycophenolate for dogs eye inflammation
Abstract
Abstract The present study aimed to describe the use of systemic mycophenolate as a steroid‐sparing therapy for immune‐mediated ophthalmic disease. Records for canine patients with suspected or confirmed immune‐mediated ophthalmic disease were retrospectively reviewed for patient signalment, diagnoses, mycophenolate dose, concurrent medications, reported side effects, and long‐term outcome while receiving systemic mycophenolate. Patient diagnoses included: anterior uveitis, panuveitis, presumed immune‐mediated retinopathy, retinal detachment, chorioretinitis, optic neuritis, and/or uveodermatologic syndrome. Overall, 18 of 23 (78%) patients had either a complete or partial response to therapy. Only six of 18 (33%) patients with a complete or partial response to therapy continued to require adjunct systemic immunosuppressive/anti‐inflammatory therapy. Gastrointestinal side effects were reported in five of 23 (22%) patients; one of these cases resolved with a 50% mycophenolate dose decrease while maintaining good control of intraocular inflammation. In conclusion, systemic mycophenolate may be considered as an adjunct or sole therapy for medical management of canine immune‐mediated ophthalmic disease.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1002/vrc2.100